Intranasal Ketorolac Tromethamine

Small molecule

Intranasal Ketorolac Tromethamine is one of 38 small molecule programs targeting Renal Colic. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Renal ColicActive, not recruiting

Renal ColicPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

52 competitors in Renal Colic

#DrugCompanyPhaseTrials

MS Contin

HHikma Pharmaceuticals LLC

Approved

6 2

Duragesic

CCephalon

Approved

2 3

Oruvail

WWyeth-Lederle Vaccines

Approved

2 4

Naropin

FFresenius Kabi Oncology Ltd.

Approved

2 5

Celebrex

PPhiladelphia Eye Associates

Approved

1 6

Paracetamol

GSK

Approved

4 7

Demerol

QQuagen

Approved

1 8

Suboxone

IIndivior Inc.

Approved

1 9

Keterol

PPamukkale University

Approved

1 10

Ketalar

AAultman Health Foundation

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Not yet recruiting

Nerve Block

NCT07305883

Clinical

Trials by Indication[1]

Nerve Block1 trial

Comparison of Intranasal Ketorolac and Intranasal Ketamine in Digital Nerve Block Pain

Not yet recruiting·TTehran University of Medical Sciences·Phase 3·NCT07305883·64 enrolled

Renal Colic1 trial

Atomized Intranasal Vs Intravenous Ketorolac in Acute Renal Colic Pain Management.

Completed·OOman Medical Speciality Board·Phase 2/3·NCT04441762·171 enrolled

Major Abdominal Surgery1 trial

Safety and Efficacy of Multiple Doses of Intranasal Ketorolac in Postoperative Pain Following Major Abdominal Surgery

Completed·EEgalet Ltd·Phase 3·NCT00266786·321 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Intranasal Ketorolac Tromethamine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intranasal Ketorolac Tromethamine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intranasal Ketorolac Tromethamine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tehran University of Medical Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: TTehran University of Medical Sciences

Intranasal Ketorolac Tromethamine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Nerve Block1 trial

Renal Colic1 trial

Major Abdominal Surgery1 trial

References

Drug Info

Quick Facts

Related News